Search results
Characterizing the Reimbursement Landscape for Cell and Gene Therapies
The rapid advancements in cell and gene therapies have transformed the treatment landscape for various conditions, including cancer, genetic disorders,
and autoimmune diseases. However, the reimbursement environment for these groundbreaking therapies presents unique challenges and opportunities. In
this session, Monet Stanford, PharmD, Director of Access & Reimbursement Policy at the Alliance for Regenerative Medicine, will explore the current realitie…
Deception in the DACH, 5 Key Trends in the Fraud and Digital Payments Landscape
Join us for an insightful webinar as we explore the latest trends in the fraud landscape across the DACH region. Our experts will provide actionable insights to
help you stay ahead of emerging threats and protect your organisation. Key Topics: Digital Banking and Financial Literacy: Understand the current state of
digital banking adoption and the importance of consumer education. Fraud Reimbursement and Regulation: Explore new regulations around Authorised Pus…
Late Phase Research | HTA: Emphasizing the Need in HTA Evaluation
Health technology assessments (HTAs) play a critical role in the creation of medical, public health, and social policies that help ensure the right patients have
access to the right treatments at the right time and at the right cost. Outcomes from late-phase research are valuable in achieving positive HTA
recommendations because they provide insight into not only the efficacy and safety of a drug, but also the patient’s needs, patient-relevant benefits, and e…
Navigate Healthcare's Dual Challenge: Timely Care Delivery & Cyber Resiliency
In today's rapidly evolving healthcare landscape, sustaining world-class care delivery and fortifying cyber resilience have become central priorities for health
systems worldwide. The urgency for a robust technology strategy has intensified as the industry recovers from the financial strain of reduced
reimbursements, expense inflation, and cybersecurity challenges. Over the next 18-24 months, healthcare leaders must focus on strategies that drive reve…
![[DIA Europe 2024] HTA Townhall – Ready for 2025 EU Joint Clinical Assessment?](https://www.brighttalk.com/portal/_next/image?url=https%3A%2F%2Fcdn.brighttalk.com%2Fams%2Fcalifornia%2Fimages%2Fcommunication%2F618326%2Fimage_988137.png%3Fwidth%3D640%26height%3D360&w=3840&q=70)
[DIA Europe 2024] HTA Townhall – Ready for 2025 EU Joint Clinical Assessment?
The EU HTA Regulation will change the HTA decision making landscape in EU and preparation is in full speed by all stakeholders. This session will address this
and other hot topics in the HTA arena. As the EU HTA Joint Clinical Assessment (JCA) will parallel the review process by Regulators, time for preparation of
both dossiers, review, decision making and alignment with subsequent national reimbursement processes will provide new challenges for industry, HTA bodi…
![[DIA Europe 2023] Use of RWE/RWD in Regulatory and HTA For Early Access Medicine](https://www.brighttalk.com/portal/_next/image?url=https%3A%2F%2Fcdn.brighttalk.com%2Fams%2Fcalifornia%2Fimages%2Fcommunication%2F588309%2Fimage_928471.png%3Fwidth%3D640%26height%3D360&w=3840&q=70)
[DIA Europe 2023] Use of RWE/RWD in Regulatory and HTA For Early Access Medicine
The developing data landscape is changing both the way medicines are being developed and their continuous assessment. Real-world data/evidence
(RWD/RWE) can bring value to every stage of a drug’s life cycle.This session provides an overview of how RWE has been used by regulatory and HTA agencies
at pre and post approval stages; explores through case studies how RWD/RWE has or could be used in the review and reimbursement for rare diseases/earl…
Navigate Healthcare's Dual Challenge: Timely Care Delivery & Cyber Resiliency
In today's rapidly evolving healthcare landscape, sustaining world-class care delivery and fortifying cyber resilience have become central priorities for health
systems worldwide. The urgency for a robust technology strategy has intensified as the industry recovers from the financial strain of reduced
reimbursements, expense inflation, and cybersecurity challenges. Over the next 18-24 months, healthcare leaders must focus on strategies that drive reve…
![[DIA Europe 2024] HTA Townhall – Ready for 2025 EU Joint Clinical Assessment](https://www.brighttalk.com/portal/_next/image?url=https%3A%2F%2Fcdn.brighttalk.com%2Fams%2Fcalifornia%2Fimages%2Fcommunication%2F620168%2Fimage_992140.png%3Fwidth%3D640%26height%3D360&w=3840&q=70)
[DIA Europe 2024] HTA Townhall – Ready for 2025 EU Joint Clinical Assessment
The EU HTA Regulation will change the HTA decision making landscape in EU and preparation is in full speed by all stakeholders. This session addresses this
and other hot topics in the HTA arena. As the EU HTA Joint Clinical Assessment (JCA) will parallel the review process by Regulators, time for preparation of
both dossiers, review, decision making and alignment with subsequent national reimbursement processes will provide new challenges for industry, HTA bodi…